Overview

The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19

Status:
Not yet recruiting

Trial end date:
2020-05-30

Target enrollment:

Participant gender:

Summary

In view of the fact that there is currently no effective antiviral therapy, the prevention or treatment of lung injury caused by COVID-19 can be an alternative target for current treatment. Patients with severe COVID-19 have rapid disease progression and high mortality. There is currently no effective treatment method, which may be related to the excessive immune response caused by cytokine storm. This study will evaluate thalidomide combined with low-dose hormone adjuvant therapy for severe COVID-19 Patient effectiveness and safety.

Phase:

Phase 2

Details

Lead Sponsor:

First Affiliated Hospital of Wenzhou Medical University

Collaborators:

Second Affiliated Hospital of Wenzhou Medical University
Wenzhou Central Hospital

Treatments:

Hormones
Thalidomide